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Healing of mucosal damage takes place in two phases: restitution of mucosal
integrity and remodeling towards recreating the original glandular arrange-
ments. These processes can be observed in several experimental rodent models:
e.g., cryoprobe or NSAID-generated ulcers in the gastric or duodenal mucosa
and following surgical resection of the small or large bowel. In some studies, it
has been possible to detect changes in the expression of peptides, either in the
reparative epithelium or adjacent to the damage, that may contribute to the heal-
ing processes. Trefoil peptides are expressed constitutively by epithelial cells in
specific regions ofthe gastrointestinal tract, in association with mucins. Several
studies have shown that trefoil peptide expression is enhanced at sites of dam-
age in man and rat, and experimental evidence supports their active participa-
tion in the healing process. Recombinant trefoil peptides are able to enhance the
rate of epithelial cell migration in vitro and are able to protect against
indomethacin-induced damage in vivo, yet they do not depend upon TGF-, for
enhancing cell migration and do not appear to affect acid secretion. The mode
of action of trefoil peptides appears to be receptor-mediated but is not simple.
There is good evidence that there are interactions between members of the tre-
foil family and the EGF family that are beneficial for mucosal defense and
repair. This raises the possibility that combining trefoil peptides with other
growth factors or small molecules may be advantageous for treatment of ulcer-
ation.
INTRODUCTION
Rapid restoration ofmucosal integrity in the gastrointestinal tract is an important step
in preventing the progression of small foci of damage into significant ulcers. Movement
ofepithelial cells to seal small breaches occurs swiftly and without the need for cell divi-
sion [1].
A variety of gut peptides are able to increase the motility of epithelial cells, includ-
ing epidermal growth factor (EGF)c, transforming growth factor-a (TGF-a), interleukin-
1-3 (IL-I-f) and interferon-y (IFN-y). These appear to have their "motogenic" effects via
increased expression ofTGF-,B [2, 3, 4]. Exactly how these peptides enhance cell migra-
tion is not known; migration depends upon the balance ofspatial and temporal signals that
regulate cell adhesion to substrate and to othercells and is dependent upon the ordered
formation and breakdown of adhesive complexes that attach the cytoskeleton to integrin-
matrix anchors [5].
Other peptides affect the remodeling following more extensive damage. Basic fibrob-
last growth factor (bFGF) is a potent angiogenic agent that facilitates healing in experi-
mental models and perhaps also in man [6, 7, 8]. Trefoil peptides are the most recent addi-
tions to the list ofgut repair peptides [9, 10]. In this article, we review evidence that trefoil
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peptides are involved directly in processes relevant to gastric ulcer healing and present new
data indicating that trefoil peptide expression is altered during the healing ofsurgical anas-
tomoses in the rat.
TREFOIL PEPTIDES
The trefoil peptide family was named originally after the three-looped (three-leaf)
structures proposed to be formed by intramolecular disulphide bonding in porcine spas-
molytic polypeptide (SP), pS2 and Xenopus spasmolysin [11]. Subsequently, detailed
structural information obtained by X-ray crystallography [12] and nmr spectroscopy [13]
confirmed the cysteine bridging pattern ofporcine SP and established the trefoil motif as
a distinct structural unit with a compact structure.
In man, rat and mouse, three trefoil peptides are known: pS2, a single-trefoil peptide
expressed at high levels in the stomach [14, 15]; SP, a double-trefoil peptide also
expressed at high levels in the stomach [15, 16, 17], particularly by antral glands [18, 19],
and additionally by Brunner's glands in the duodenum [15, 19, 20, 21]; and ITF (intesti-
nal trefoil factor) a single-trefoil peptide abundant in goblet cells throughout the small and
large bowel [22, 23, 24, 25, 26]. In each case, the trefoil peptide is co-expressed with one
or more mucin genes, although in some circumstances, pS2 expression can occur in neu-
roendocrine cells [27, 28]. In Xenopus, additional trefoil peptides are known, some of
which are expressed contiguous with mucin core peptide sequences so that combined tre-
foil-mucin molecules can be made [29].
TREFOIL PEPTIDE EXPRESSION AND ULCERATION
Several studies have used immunohistochemical and in situ hybridization methods to
determine the patterns ofexpression of trefoil peptides in normal and ulcerated endoder-
mal tissues. These have indicated that there is enhanced, and sometimes ectopic, expres-
sion of trefoil peptides adjacent to ulcers [17, 30, 31, 32] within the sheet of epithelial
cells presumed to be advancing over the ulcer base, in regenerative glands at the ulcer
margins, and occasionally in nearby goblet or neuroendocrine cells. In chronic ulceration,
local production of trefoil peptides together with EGF and TGF-a is augmented by the
development ofglands of an ulcer-associated cell lineage (UACL), and this is the subject
of the next section of these proceedings.
One problem with studying archival clinical materials is that the chronology ofalter-
ations in gene expression cannot be established. Potentially, and if acceptable on ethical
grounds, serial biopsies might be taken endoscopically from a lesion, but with the com-
plication that sampling itself could trigger a further response. One way to circumvent
these problems and learn about the sequence of events following ulceration is to use ani-
mal models.
Trefoilpeptide expression during healing ofcryoprobe ulcers in rat stomach
Application of a liquid nitrogen chilled rod to the exterior wall ofthe stomach of an
anaesthetized rat produces a "freeze burn" that is reproducible in size and rate ofhealing.
This model was used to establish [33] that increased levels ofrSP mRNA (relative to that
encoding the cytoskeletal protein f3-actin) were produced rapidly in response to lesioning
gastric body; the ratio was almost doubled between 30 min and two hr after freezing and
then normalized. Normal body mucosa showed rSP expression in mucous neck cells. This
persisted after ulceration, together with very strong signals for rSP andP-actin mRNAs in
the regenerative glands. There was no detectable rITF mRNA in normal rat stomach (con-
sistent with earlier observations) or in the first 24 hr of ulcer formation; levels increased
from day two to three then decreased over the next week, by which time occasional ITF-
expressing mucous cells in regenerative glands were detectable by in situ hybridization.
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The relative levels of mRNAs encoding EGF and TGF-a did not increase as quickly as
that of rSP or to such an extent as that of rITF. Analysis of control trephines of gastric
body mucosa showed that there were no field changes increasing the expression ofany of
these mRNAs.
Immunohistochemical studies [33] indicated that SP synthesized by regenerative
glands was able to leak through into the submucosa, where it might be predicted to exert
the spasmolytic properties after which it was named [34].
Subsequently, it was possible to examine the expression ofrpS2 by in situ hybridiza-
tion using the same histology blocks. The mRNA for rpS2 is normally found in the super-
ficial epithelial cells [15]. Figure 1 shows the distribution of rpS2 mRNA in sections
through rat stomach at six hr (Figure la) and 24 hr (Figures lb and ic) after application
of the cryoprobe. From such images, it seems there is accentuation ofrpS2 signals in the
glands closest to the damage at these early times. Unfortunately, it was not possible to
quantify these changes in the same way as the other four peptide mRNAs because all of
the RNA extracted had been used.
Trefoil peptide expression in response to NSAIDs
In contrast to the deep focal lesions produced by cryoprobe or topical application of
acetic acid, indomethacin or ASA treatments produce erosions whose boundaries can be
more difficult to detect. Immunohistochemically,-the expression ofrSP in the gastric body
mucosa is altered within a few hours ofindomethacin (s.c.); the zone ofexpression broad-
ens and extends much more basaly beneath superficial erosions [35]. ASA also disrupts
the pattern ofrSP, assessed immunohistochemically and by in situ hybridization, but it has
been very difficult to relate these changes to the histology (Yeomans and Poulsom, unpub-
lished observations).
Trefoilpeptide expression during healing ofsurgical anastomoses
We have set out to study the healing process following surgical resection ofeither the
small or large bowel in rats to see if the tongue of epithelium that extends to cover the
ulcer base expresses all three trefoil peptides as it can do in ulcerated regions ofthe bowel
in patients with Crohn's disease. Also, resection of the bowel is a common surgical pro-
cedure in which the restoration of mucosal integrity might potentially be impaired by
chemotherapy and or radiation, and we wondered if it may be possible to use this model
to evaluate peptides as therapeutic agents to improve healing rates.
We found that the rate ofmucosal healing (simply to restore gross mucosal integrity)
was extremely variable between subjects. Nevertheless, a number of observations were
made at times between four and 21 days where there were still breaks in the mucosa: 1)
enhanced expression of rITF mRNA near the ulcer in loose glandular structures (Figures
la and lb) and in many cells ofthe extending epithelial sheet (Figure 1c) (including those
not resembling goblet cells) (see also Figure 2); 2) ectopic expression of rSP mRNA and
immunoreactivity in crypts near the resection (data not shown).
BIOLOGICAL PROPERTIES OF TREFOIL PEPTIDES
The only trefoil peptide to be purified in more than mg quantity from natural sources
is porcine pancreatic spasmolytic polypeptide, which was discovered in a side fraction
produced during the preparation ofporcine insulin; it had a notable resistance to proteol-
ysis and thermal denaturation [36]. This peptide corresponds to the SPs known in man,
mouse and rat, although expression in the human pancreas seems to occur only in
response to chronic inflammation [17]. Early characterization suggested that PSP was able
to inhibit gastric acid secretion and muscle contraction [34], stimulate the proliferation of
some epithelial cell lines in culture [37] and bind to intestinal epithelial cell membrane
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Figure 1. Expression of rpS2 mRNA in rat stomach following application of a cryoprobe. At
six hr, pS2 mRNA (black autoradiographic silver grains) is localized to the superficial mucosa and
appears more abundant in the glands nearest the damage, which is present on the right side of the
picture (a, top). After 24 hr, the glands nearest to the damage are expressing pS2 mRNA in a broad-
er zone than normal ([b, center], bright field illumination, and [c, bottom], reflected-light dark-field
view to show autoradiographic grains in white).Poulsom et al.: Functions oftrefoilpeptides
Figure 2.Expression ofrITF mRNA in ratsmall bowel 14days after surgical resection. (a, top)
normal crypt/villus architecture isjust visible ontheleft margin. There is ahigh level ofrITFmRNA
(black autoradiographic silver grains) in the regenerative glands at the margin of an extensive ulcer.
(b, center) higher power reflected light dark-field view indicating that the regenerative glands show
strong expression of rITF mRNA as do goblet cells in the rest of the intestine (the original section
was counterstained by Giemsa's method which results in a gold-coloured reflection easily discrim-
inated from silver grains in colour but not monochrome figures). (c, bottom) a region contiguous
with that in (b) showing that the tongue of cells extending part way over the base of the ulcer (top
left) expresses rITF mRNA.
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receptors [38, 39]. Such properties would be highly desirable in a peptide designed to
assist ulcer healing but have been difficult to reproduce. For example, the ability of PSP
to promote proliferation in vitro appears dependent upon the presence of glutathione in the
culture medium [40,411, and in vivo, no effects ofPSP could be detected [41]. Significant
progress in learning the functions oftrefoil peptides has become possible only recently, as
they have been produced using recombinant DNA technology.
Rat ITF was first made as a fusion protein in E. coli and used to probe for trefoil bind-
ing sites [42]; subsequently, the mature rITF peptide was made using E. coli [43], yeast
[44, 45] and baculovirus systems [2, 46], and a mutated form [43], in which the unpaired
7th cysteine is replaced with serine, was made to test the hypothesis that ITF can exist as
a dimer, mimicking the two-trefoil structure of PSP.
Two forms of human SP, one unavoidably glycosylated, have been purified in gram
quantities following expression in yeast [44]. Like PSP, hSP exhibits resistance to pro-
teases, even in human gastric and intestinal juice [35], and is able to exert mild prolifera-
tive effects in cell culture [40].
Human pS2 has been made in E. coli [47] and B. subtilis [48] and as the natural
mature peptide and as a variantin which the 7th cysteine has been replaced by serine [49].
A transgenic mouse strain was produced that secreted humanpS2 in milk [50] but with-
out effects upon breast morphology or nursing pups.
Motogenic effects oftrefoil peptides
Variations of the "wounded cell monolayer" experiment have been used to establish
that rITF, hITF and hSP are able either to increase the numbers of epithelial cells migrat-
ing into the "wound" from the edge or to increase the rate at which a wound gap closes
[2, 3, 4, 35, 51]. Many studies assess the effects oftest compounds after 24 hr, which may
mean that any effect is not strictly modeling restitution; nevertheless, it is clear from time-
course studies that hSP and rITF do improve the advance of the wound edge in the first
few hours, with the rate then slowing to that of control wounds, possibly as the peptides
become inactivated [35, 51]. The motogenic effects of ITF and hSP differ from that of
EGF and TGF-a in that the trefoil effects are not mediated via TGF-f [2, 35].
Mitogenic effects oftrefoil peptides
There was much interest in the possibility that pS2 was able to cause cell prolifera-
tion because it is expressed in approximately 50 percent of breast cancers. However, no
such effects have been found [52]. Both PSP and hSP have weak proliferative activity in
vitro depending upon the cell line and the glutathione status of the medium and cells (see
above). There are no claims that ITF is proliferative, in fact some data support ITF being
anti-proliferative [2].
Ulcerprevention by trefoil peptides
Pretreatment ofrats with subcutaneous ITF orhSP is able to prevent, in a dose-depen-
dent manner, much of the macroscopic hemorrhagic damage produced in response to a
single subcutaneous dose of indomethacin [35, 51]. Oral doses of trefoil peptides appear
to be less effective [46], possibly because the trefoil receptor [53] is located basolaterally
on the epithelial cell membranes.
Synergy between rITFand EGF
Doses of EGF and rITF given subcutaneously that are themselves ineffective in
reducing indomethacin-induced gastric damage are very effective when given together
[51]. This synergy occurs in an assay that is performed over three to four hr, so it is pos-
sible that the benefit is due in part to complex interactions involving altered expression of
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genes; the presence of an EGF-response element in the pS2 gene [54] shows that there is
some functional relationship between the trefoils and EGFR-ligands, and there is evidence
that bFGF can increase pS2 expression [55, 56]. Yet much more direct interactions occur.
Electrophysiological studies of isolated gut mucosa and cell lines in Ussing chambers
have showed that both EGF and rITF (but not hSP or PSP) rapidly increase electrogenic
chloride transport when applied basolaterally [57]. The response to a maximally effective
concentration of EGF (InM) is increased further by adding rITF; the enhancing effect of
rITF had a bell-shaped dose response below 10-7 M [58].
Other effects oftrefoilpeptides
Early observations reported that PSP could inhibit pentagastrin-stimulated gastric
acid secretion [34] although recombinant hSP does not affect gastric pH [35]. There is
speculation that trefoil peptides interact with mucus, e.g. [59], although there is as yet lim-
ited evidence that they do [60].
CONCLUSION
A growing body of evidence supports the view that trefoil peptides are important in
the maintenance ofmucosal integrity and may be actively involved in the healing ofdam-
age. It is not certain whether the properties oftrefoil peptides could be useful therapeuti-
cally in peptic ulcer disease, but their potential for reducing NSAID-damage and chronic
ulceration in Crohn's disease and ulcerative colitis may merit further study.
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